XClose

Institute for Global Health

Menu

CASCADE Study

An investigation into the medical and lived experiences of people with recently acquired HIV in Europe and Canada.

HIV in the current day

Antiretroviral therapies (ART) and pre-exposure prophylaxis (PrEP) have been revolutionary in the fight against HIV. Despite this, in 2019 an estimated 21,793 people were newly diagnosed with HIV in Western-Europe. An understanding of the circumstances around contracting HIV is crucial to elimination efforts.

Our aim

The CASCADE study aims to understand the experiences and needs behind the use or disuse of prevention methods, including PrEP, from the people who are most affected. With better research and understanding we hope to impact HIV health strategies to better serve key populations.

The CASCADE study is a multi-centre study funded through grants from; ViiV Healthcare UK, Janssen Pharmaceutica NV and Merck Sharp & Dohme Corporation.

Key Project Information

Dates: January 2022 to December 2024

Status: Current

UCL lead/Principal Investigator: Professor Kholoud Porter

Partners: InfCare (Sweden), Southern Alberta (Canada), Aquitaine (France),  FHDH (France), PRIMO (France), CoRIS (Spain), AMACS (Greece) and ATHENA (Netherlands)

Participating Sites

CASCADE has many participating sites across Western Europe and Canada. 

Explore our cohorts.

Contact us

For any inqueries, email us at CASCADE@ucl.ac.uk.

Follow us on X.

Cascade logo